BEIJING, Nov. 28, 2016 -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), announced today that its Board of Directors has unanimously approved the extension of its Rights Agreement, presently scheduled to expire on December 2, 2016, for another year.
As the Rights Agreement was designed to ensure that all shareholders of the Company receive fair and equal treatment in the event that an unsolicited attempt is made to acquire the Company outside of the process led by a special committee of independent directors, the Board and the special committee have determined that it is advisable and in the best interests of the Company and its stockholders to extend the Rights Agreement for an additional year, as the special committee continues to consider and evaluate the proposal submitted by Yunfeng Capital to acquire the Company.
About iKang Healthcare Group, Inc.
iKang Healthcare Group, Inc. is the largest provider in China’s fast growing private preventive healthcare services market, accounting for approximately 13.6% of market share in terms of revenue in calendar year 2014.
Through iKang’s integrated service platform and established nationwide network of medical centers and third-party service provider facilities, the Company provides comprehensive and high quality preventive healthcare solutions, including a wide range of medical examination services and value-added services including disease screening and other services. iKang’s customers are primarily corporate customers who contract with the Company to provide medical examination services to their employees and clients, and pay for these services at pre-negotiated prices. iKang also directly markets its services to individual customers. In the fiscal year ended March 31, 2016, the Company served a total of 4.6 million customer visits under both corporate and individual programs.
As of November 28, 2016, iKang’s nationwide network consisted of 96(1) self-owned centers covering 28 of the most affluent cities in China, namely Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha, Yantai, Yinchuan, Weihai, Weifang, Shenyang, Xi’an, Wuhu, Guiyang, Ningbo, Jinan and Foshan as well as Hong Kong. The Company has also supplemented its self-owned medical center network by contracting with approximately 400 third-party service provider facilities in over 150 cities, which include select independent medical examination centers and hospitals across all of China’s provinces, creating a nationwide network that allows iKang to serve its customers in markets where it does not have self-owned medical centers.
(1) Among the 96 self-owned medical centers, 2 medical centers are currently operated primarily by the minority shareholders of these medical centers or their parent company.
Forward-looking statements
This press release contains forward-looking statements. These statements, including management quotes and business outlook, are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “estimate,” “project,” “predict,” “believe,” “expect,” “anticipate,” “intend,” “potential,” “plan,” “goal” and similar statements. iKang may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s goals and strategies; its future business development, financial condition and results of operations; its ability to retain and grow its customer base and network of medical centers; the growth of, and trends in, the markets for its services in China; the demand for and market acceptance of its brand and services; competition in its industry in China; relevant government policies and regulations relating to the corporate structure, business and industry; fluctuations in general economic and business conditions in China. Further information regarding these and other risks is included in iKang’s filing with the Securities and Exchange Commission. iKang undertakes no duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
IR Contact: iKang Healthcare Group, Inc. Christy Xie Director of Investor Relations Tel: +86 10 5320 8599 Email: [email protected] Website: www.ikanggroup.com FleishmanHillard Ruby Yim Email: [email protected]


Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Britain Courts Anthropic Amid US Defense Department Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 



